From targeted laboratory-scale investigations, such as initial compound screening or mechanistic studies, to high-throughput screening of large sample cohorts for biomarker discovery, our service adapts seamlessly to your project's volume and scope.
CD44v6 Assay Portfolio Service
Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
At Creative Biolabs, our CD44v6 assay portfolio service is designed to provide specific, actionable insights into CD44v6 expression and function, directly addressing critical research and development needs. We deliver quantitative data on CD44v6 levels, characterize its role in cellular processes, and evaluate its impact on therapeutic responses. Creative Biolabs empowers you to identify novel biomarkers, validate drug targets, and understand mechanisms of resistance.
The Biology of CD44v6
CD44v6 is a critical variant isoform of the CD44 transmembrane glycoprotein, emerging from alternative mRNA splicing. Its unique ectodomain structure facilitates interactions with extracellular matrix components like hyaluronic acid and various growth factors, activating key signaling pathways. Overexpression of CD44v6 is strongly linked to cancer progression, metastasis, and therapeutic resistance, making it a pivotal target for biomarker discovery and therapeutic intervention. Research has consistently highlighted its involvement in tumor invasiveness, cancer stem cell maintenance, and evasion of apoptosis.
Discover how we can help - Request a consultation.
Fig.1 The interaction between CD44v6 and HA.1
What We Can Offer
Comprehensive Assay Scalability
Optimized Assay Development & Data Processing
Benefit from our efficient upstream assay development, where protocols are meticulously fine-tuned for optimal sensitivity and specificity, and our meticulous downstream data processing. This comprehensive approach ensures rapid and reliable results, translating directly into accelerated decision-making and faster progression of your research or drug development pipeline.
Extensive Capacity for Large-Scale Projects
Our advanced platforms and substantial operational capacity mean we can handle extensive sample sets, including large clinical cohorts or high-volume compound libraries. This robust infrastructure allows us to deliver high-quality data without compromising turnaround times, even for the most demanding and complex high-throughput studies.
Flexible Assay Modes
Whether you require discrete batch processing for comparative studies, fed-batch analysis for time-course experiments, or continuous monitoring for dynamic biological processes, our flexible assay modes are tailored to meet your precise experimental design.
Workflow of CD44v6 Assay Portfolio Service
Highlights
Unrivaled Expertise & Experience
We possess a profound understanding of CD44v6 biology, ensuring the use of highly specific antibodies and reagents, minimizing off-target binding, and maximizing data integrity. This deep scientific acumen is the foundation of our reliable and insightful results.
Cutting-Edge Technology & Comprehensive Assay Modalities
We leverage state-of-the-art analytical platforms and methodologies for all our CD44v6 assays. Our comprehensive portfolio includes ELISA, flow cytometry, immunohistochemistry (IHC), immunofluorescence (IF), western blot, and quantitative PCR (qPCR).
Robust Quality Control & Reproducibility
Every assay is performed under stringent quality control, adhering to industry best practices and incorporating QbD and PAT. This guarantees the reliability, consistency, and reproducibility of your data, providing absolute confidence in your scientific conclusions.
Accelerated Research & Cost-Effectiveness
By partnering with Creative Biolabs, you can significantly reduce your experimental workload and accelerate research timelines. Our optimized workflows provide a highly cost-effective solution compared to in-house capabilities, allowing you to reallocate valuable internal resources.
Experience the Creative Biolabs advantage - Get a quote today.
Customer Reviews
-
Enhanced Drug Screening
Using Creative Biolabs' service in our drug screening has significantly improved our ability to identify compounds that modulate CD44v6 expression, leading to more targeted therapeutic candidates. We appreciate the detailed report and the team's responsiveness. - Sh K*r.
-
Overcoming Resistance
Creative Biolabs' service provided deep insights into CD44v6's role in drug efflux and autophagy, helping us design more effective combination therapies. Their team also offered valuable advice on sample handling to ensure optimal results. - Ma L*o.
FAQs
How can Creative Biolabs' CD44v6 assay portfolio service help me identify new therapeutic targets?
Our comprehensive service provides a detailed analysis of CD44v6 expression, signaling pathways, and interactions with other molecules. By precisely quantifying CD44v6 in various biological contexts, we help you uncover its specific roles in disease progression, thereby revealing novel points of intervention for therapeutic development.
How does this service compare to in-house CD44v6 assay development?
Creative Biolabs offers validated, high-sensitivity assays performed by experienced specialists using state-of-the-art equipment, often surpassing the capabilities of in-house setups. This translates to faster turnaround times, reduced operational costs, and highly reproducible data.
Related Services
Biomarker Discovery Panels
This service facilitates multi-omics approaches, integrating CD44v6 expression data with other protein, genetic, or metabolic markers.
Learn More →Cell Line Development Service
We offer a comprehensive service to create stable, high-yield cell lines with altered CD44v6 expression, optimized for functional studies and drug screening.
Learn More →How to Contact Us
Creative Biolabs' CD44v6 assay portfolio service provides a robust and comprehensive solution for researchers and pharmaceutical companies seeking deep insights into this critical biomarker. Leveraging our extensive expertise and advanced platforms, we deliver precise, actionable data to accelerate your drug discovery, biomarker validation, and therapeutic development efforts.
Contact us for more information and to discuss your project.
Reference
- Ma, Lixin, Lihua Dong, and Pengyu Chang. "CD44v6 engages in colorectal cancer progression." Cell death & disease 10.1 (2019): 30. Distributed under an Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1038/s41419-018-1265-7
Download our brochureLoading case studies...
Online Inquiry